Navigation Links
Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
Date:4/27/2009

d clinical development positions for Novartis Pharma. Dr. Scaife began his career as the Regulatory and Medical Affairs Manager at Johnson & Johnson Medical Ltd., UK.

Dr. Scaife received a Ph.D. in Toxicology from Leicester School of Pharmacy, United Kingdom and a B.S. degree in Pharmacology from the University of Bath, United Kingdom.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the enrollment, timing and completion of clinical trials of Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
2. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
3. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
4. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
5. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
6. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
7. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
8. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
9. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
10. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
11. United Therapeutics to Announce 2009 First Quarter Financial Results Before Market Open on Friday, May 1, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... April 21, 2015  Scientists from the J. ... organization, published a paper today outlining new synthetic ... called diatoms. The researchers, led by first author ... Philip Weyman , Ph.D., conclude that these ... of diatom genetics and thus facilitate advances in ...
(Date:4/21/2015)... , April 21, 2015 Merrimack Pharmaceuticals, ... from a multi-arm Phase 1 study of MM-141, a ... presented in an oral session by Dr. Mansoor ... Cancer Research Annual Meeting in Philadelphia, PA. ... of MM-141 as a monotherapy and in combination with ...
(Date:4/21/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... April 23, 4:30 p.m. ET. Participants are invited to ... Investor call information: U.S./ Canada ... (925) 418-7845 Participant Passcode: 32888538 Questions can ... tina.amirkiai@fleishman.com . Access will be provided ...
(Date:4/21/2015)... 21, 2015  Cryoport, Inc. (OTCBB: CYRX) ... logistics solutions for the life sciences industry, ... lines, clinical research organizations, vaccine manufacturers and ... Mark W. Sawicki , Chief Commercial Officer, ... Summit in San Francisco, CA ...
Breaking Biology Technology:Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 2Scientists at the J. Craig Venter Institute Publish Paper Outlining Efficient Synthetic Biology Methods to Genetically Engineer Microalgae 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 2First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 3First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 4First-in-Human Phase 1 Trial of MM-141 Demonstrates Activity in Biomarker Positive Patients 5Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 2Cryoport to Present at the 3rd Annual BioLogistics Summit in San Francisco, CA 3
... Soyfoods Even HealthierST. LOUIS, March 31 Recent research ... to be beneficial to the diet. And, the majority ... products such as soyfoods even healthier. These findings come ... Survey - sponsored by the United Soybean Board ...
... 30 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced its financial results for the fourth ... are very happy to report that our partner Auxilium ... enrollment in a Phase IIb trial in Peyronie,s disease ...
... 30 Mylan Inc. (Nasdaq: MYL ) ... in which it holds a 71.2% controlling interest, has ... and Drug Administration (FDA) under the President,s Emergency Plan ... Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 7Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... with a number of pathological conditions, including cancer. Publishing in ... in drinking water given at the maximum levels permitted ... in mice. On the other hand, reducing copper levels reduced ... essential factor for the growth of tumors in humans as ...
... Hall Institute have been awarded more than $2.2 million from ... disorders and inflammatory diseases. Three institute researchers - ... - were announced last week as recipients of ARC Future ... body controls errant immune cells that cause type 1 diabetes ...
... , Nov. 14, 2013  Based on its recent research ... presents Cognitec Systems GmbH with the 2013 European ... Cognitec,s blinkers-on focus on face biometrics earned the ... to develop its flagship face recognition technology, FaceVACS-VideoScan. ...
Cached Biology News:Copper intake makes tumors breathe 2ARC Future Fellows awarded $2.2M for immune and inflammation studies 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
5,6 Carboxyfluorescein is conjugated to BSA (bovine serum albumin) protein through amide bonds....
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Serum Albumin protein through lysine by amide bonds....
... Edwards (1996) • Provides key ... immunoassays, including RIA, ELISA and ... the photoluminescent and chemiluminescent labels ... also given on assay design ...
EoProbe Eosinophil Staining Kit, 1 Kit...
Biology Products: